Evidence map›Paper›PMID 40133809›Full record

ArticleMolecular medicine (Cambridge, Mass.)2025

Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer.

Ana Lameirinhas, Sandra Torres-Ruiz, Iris Garrido-Cano, Cristina Hernando, María Teresa Martínez, Ana Rovira, Joan Albanell, Sandra Zazo, Federico Rojo, Begoña Bermejo and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ana Lameirinhas *INCLIVA Biomedical Research Institute, Valencia, 46010, Spain.
Sandra Torres-Ruiz *INCLIVA Biomedical Research Institute, Valencia, 46010, Spain.
Iris Garrido-CanoINCLIVA Biomedical Research Institute, Valencia, 46010, Spain.
Cristina HernandoINCLIVA Biomedical Research Institute, Valencia, 46010, Spain.
María Teresa MartínezINCLIVA Biomedical Research Institute, Valencia, 46010, Spain.
Ana RoviraCenter for Biomedical Network Research on Cancer (CIBERONC), Madrid, 28019, Spain.
Joan AlbanellCenter for Biomedical Network Research on Cancer (CIBERONC), Madrid, 28019, Spain.
Sandra ZazoCenter for Biomedical Network Research on Cancer (CIBERONC), Madrid, 28019, Spain.
Federico RojoCenter for Biomedical Network Research on Cancer (CIBERONC), Madrid, 28019, Spain.
Begoña BermejoINCLIVA Biomedical Research Institute, Valencia, 46010, Spain.
Ana LluchINCLIVA Biomedical Research Institute, Valencia, 46010, Spain.
Juan Miguel CejalvoINCLIVA Biomedical Research Institute, Valencia, 46010, Spain.
Eduardo TormoINCLIVA Biomedical Research Institute, Valencia, 46010, Spain. tormared@gmail.com.
Pilar ErolesINCLIVA Biomedical Research Institute, Valencia, 46010, Spain. pilar.eroles@uv.es.

Funding

Asociación Española Contra el Cancer PRDVA19016LAMEConselleria d'Educació, Investigació, Cultura i Esport, Generalitat Valenciana ACIF/2019/119European Union-Next generation EU Margarita Salas postdoctoral grantSociedad Española de Oncología Médica Río Hortega-SEOMSpanish Government and cofinanced by FEDER Funds PI21/00002Spanish Government and cofinanced by FEDER Funds PI21/00142Spanish Government and cofinanced by FEDER Funds PI21/01351Spanish Government CIBERONC CB16/12/00241Spanish Government CIBERONC CB16/12/00481
6 · The paper itself

Abstract

The anti-HER2 monoclonal antibody trastuzumab and new derivative formulations are the standard treatment for HER2-positive breast cancer. However, after 1 to 5 years of treatment, some patients acquire resistance to therapy, leading to relapse. The microRNA-449 family members were downregulated in HER2-positive breast cancer cell lines and low levels were associated with patients' worse prognosis. Moreover, trastuzumab-resistant HER2-positive breast cancer cell lines showed lower microRNAs-449 and higher Fatty Acid Synthase (FASN) expression, compared to sensitive cell lines. The direct regulation of FASN by microRNA-449a and microRNA-449b-5p was demonstrated. Moreover, microRNAs-449 overexpression and FASN inhibition decreased cell proliferation and sensitized cells to trastuzumab treatment by inhibiting the PI3K/AKT signaling pathway. Together, these results suggest the microRNAs-449/FASN axis as a potential therapeutic target in combination with anti-HER2 agents to overcome trastuzumab resistance and to improve treatment response in HER2-positive breast cancer patients.

Indexed as

Antineoplastic Agents, ImmunologicalBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFatty Acid Synthase, Type IMicroRNAsTrastuzumabCell Line, TumorCell ProliferationDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansPrognosisProto-Oncogene Proteins c-aktSignal TransductionAntineoplastic Agents, ImmunologicalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesFASN protein, humanFatty Acid Synthase, Type IMicroRNAsMIRN449 microRNA, humanProto-Oncogene Proteins c-aktTrastuzumabBreast cancerFASNHER2microRNAs-449Trastuzumab

Identifiers

PMID40133809
PMCPMC11938741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.